Results of the phase 3 VITAL study of NEOD001 (birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for Mayo stage IV patients Meeting Abstract
| Authors: | Gertz, M. A.; Cohen, A. D.; Comenzo, R. L.; Du Mond, C.; Kastritis, E.; Landau, H. J.; Libby, E. N. 3rd; Liedtke, M.; Merlini, G.; Sanchorawala, V.; Schönland, S. O.; Wechalekar, A. D.; Zonder, J. A.; Kinney, G. |
| Abstract Title: | Results of the phase 3 VITAL study of NEOD001 (birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for Mayo stage IV patients |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577160407291 |
| DOI: | 10.1182/blood-2019-124482 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3166 -- Source: Wos |
